All 2 tracked stories fall under one category: pharma. Of the tracked stories, 2 of 2 also mention AbbVie, the most common co-covered peer. That works out to roughly 0.1 stories per week across a 152-day span. Source depth averages 2 original sources per story, versus 3.9 across the same-window beat baseline.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Rinvoq
All 2 tracked stories fall under one category: pharma. Of the tracked stories, 2 of 2 also mention AbbVie, the most common co-covered peer. That works out to roughly 0.1 stories per week across a 152-day span. Source depth averages 2 original sources per story, versus 3.9 across the same-window beat baseline. Their average consequence score of 5 runs below the beat's 6.3 for that window. We currently track 2 Biotech stories that mention Rinvoq, published between February 27, 2026 and July 28, 2026.
Stories tracked
2
Per week
0.1
Sources per story
2
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 514 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Rinvoq. Shared-story counts are live from our verified record — not editorial picks.
AbbVie's second-quarter results, expected to show $3.61 EPS, hinge on the continued clinical and commercial success of Rinvoq and Skyrizi. The Apogee deal underscores a deepening immunology pipeline as Humira fades into the rearview.
RBC Capital has launched coverage of pharmaceutical giant AbbVie with an Outperform rating, signaling confidence in the company's growth trajectory. The initiation suggests that market concerns regarding biosimilar competition for Humira are overstated as newer immunology assets gain significant market share.